Latest Period
Q1 2026
Security Snapshot
Lineage Cell Therapeutics, Inc. - Common shares (LCTX) Institutional Ownership
CUSIP: 53566P109
13F Institutional Holders and Ownership History from Q2 2019 to Q1 2026
Institutions Reporting
129
Shares (Excl. Options)
111,690,272
Price
$1.58
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common shares
- Symbol
- LCTX on NYSE
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 111,690,272
- Total 13F value
- $176,472,294
- Portfolio coverage rank
- 0%
- Share change
- +14,567,446
- Value change
- +$22,992,227
- Number of holders
- 129
- Shares outstanding
- 250,425,788
- SEC-reported price per share
- $1.28
- Insider filing price
- $1.28
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- LCTX - Lineage Cell Therapeutics, Inc. - Common shares is tracked under CUSIP 53566P109.
- 129 institutions reported positions in Q1 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 121 to 129 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $169,765,856 to $176,472,294.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 129 institutions filings for Q1 2026.
Security key
53566P109
Latest holder period
Q1 2026
13F holders
129
13D/G owners
3
CIK / CUSIP context first
Open Q1 2026 holders
LCTX full holder history
Lineage Cell Therapeutics, Inc. SEC filings
Lineage Cell Therapeutics, Inc. company facts
Lineage Cell Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 53566P109:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
LCTX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BROADWOOD PARTNERS, L.P. | 23% | -5.6% | $97,763,723 | 57,848,357 | 0% | NEAL C. BRADSHER | 12 Nov 2025 | |
| Chernett Jorey | 5% | $13,848,454 | 11,445,003 | Chernett Jorey | 22 Sep 2025 | |||
| BlackRock, Inc. | 1% | -80% | $2,027,626 | -$8,365,103 | 2,234,545 | -80% | BlackRock, Inc. | 30 Jun 2025 |
As of 31 Mar 2026, 129 institutional investors reported holding 111,690,272 shares of Lineage Cell Therapeutics, Inc. - Common shares (LCTX). This represents 45% of the company’s total 250,425,788 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
43%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BROADWOOD CAPITAL INC | 20% | 49,560,992 | 0% | 5.5% | $78,306,367 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.3% | 8,318,685 | 0% | 0% | $13,143,522 |
| Defender Capital, LLC. | 2.7% | 6,729,599 | -1.5% | 3.8% | $10,632,766 |
| MILLENNIUM MANAGEMENT LLC | 2.2% | 5,561,374 | +164% | 0.01% | $8,786,971 |
| RAFFLES ASSOCIATES LP | 2.1% | 5,362,788 | 0% | 7.4% | $8,473,205 |
| FIFTH THIRD BANCORP | 1.8% | 4,600,000 | 0.01% | $7,268,000 | |
| BlackRock, Inc. | 1.5% | 3,864,757 | +0.8% | 0% | $6,106,316 |
| ARMISTICE CAPITAL, LLC | 1.3% | 3,182,799 | 0.17% | $5,028,822 | |
| MARSHALL WACE, LLP | 1.2% | 3,065,033 | +125% | 0.01% | $4,842,750 |
| GEODE CAPITAL MANAGEMENT, LLC | 1% | 2,523,114 | +2.5% | 0% | $3,988,508 |
| RENAISSANCE TECHNOLOGIES LLC | 0.85% | 2,125,100 | -12% | 0.01% | $3,357,658 |
| MORGAN STANLEY | 0.75% | 1,868,491 | -6.5% | 0% | $2,952,215 |
| UBS Group AG | 0.55% | 1,370,461 | +648% | 0% | $2,165,328 |
| VANGUARD FIDUCIARY TRUST CO | 0.53% | 1,324,158 | 0% | 0% | $2,092,170 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.52% | 1,304,685 | +85% | 0% | $2,061,403 |
| GOLDMAN SACHS GROUP INC | 0.47% | 1,169,427 | -19% | 0% | $1,847,695 |
| STATE STREET CORP | 0.44% | 1,090,111 | +7.3% | 0% | $1,722,375 |
| JANE STREET GROUP, LLC | 0.4% | 993,208 | -1.2% | 0% | $1,569,269 |
| RED CRANE WEALTH MANAGEMENT, LLC | 0.24% | 597,263 | 0% | 0.78% | $943,676 |
| NORTHERN TRUST CORP | 0.2% | 499,127 | +4.1% | 0% | $788,621 |
| SEI INVESTMENTS CO | 0.17% | 422,274 | +57% | 0% | $667,195 |
| BANK OF AMERICA CORP /DE/ | 0.17% | 419,355 | +112% | 0% | $662,580 |
| BARCLAYS PLC | 0.16% | 393,309 | +13% | 0% | $621,429 |
| Informed Momentum Co LLC | 0.14% | 346,615 | -22% | 0.06% | $547,652 |
| Point72 Asset Management, L.P. | 0.12% | 304,363 | +91% | 0% | $480,894 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
28
Latest
Q1 2026
Rows shown
1-25 of 28
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 111,690,272 | $176,472,294 | +$22,992,227 | $1.58 | 129 |
| 2025 Q4 | 101,657,149 | $169,765,856 | +$22,647,526 | $1.67 | 121 |
| 2025 Q3 | 87,923,479 | $148,572,802 | -$9,340,067 | $1.69 | 111 |
| 2025 Q2 | 97,785,816 | $88,366,897 | -$8,826,258 | $0.91 | 128 |
| 2025 Q1 | 109,349,495 | $49,687,946 | +$369,638 | $0.45 | 126 |
| 2024 Q4 | 107,111,044 | $53,827,848 | +$3,921,589 | $0.50 | 119 |
| 2024 Q3 | 94,568,251 | $85,611,699 | -$260,148 | $0.91 | 112 |
| 2024 Q2 | 94,431,242 | $94,175,668 | +$447,460 | $1.00 | 110 |
| 2024 Q1 | 93,427,423 | $138,270,047 | +$26,536,201 | $1.48 | 113 |
| 2023 Q4 | 75,708,353 | $82,523,932 | +$188,614 | $1.09 | 114 |
| 2023 Q3 | 75,504,077 | $89,104,877 | -$402,119 | $1.18 | 102 |
| 2023 Q2 | 75,637,865 | $106,648,039 | +$8,457,693 | $1.41 | 105 |
| 2023 Q1 | 69,793,059 | $104,687,354 | +$7,197,215 | $1.50 | 114 |
| 2022 Q4 | 65,070,787 | $76,138,155 | +$591,571 | $1.17 | 99 |
| 2022 Q3 | 64,712,443 | $73,129,667 | -$348,315 | $1.13 | 88 |
| 2022 Q2 | 64,980,785 | $102,682,821 | -$12,116,491 | $1.58 | 84 |
| 2022 Q1 | 72,831,378 | $112,314,619 | -$3,915,128 | $1.54 | 99 |
| 2021 Q4 | 73,975,180 | $181,237,026 | -$5,349,258 | $2.45 | 110 |
| 2021 Q3 | 75,827,690 | $191,741,083 | +$6,640,880 | $2.52 | 106 |
| 2021 Q2 | 73,147,470 | $208,518,897 | +$38,013,987 | $2.85 | 103 |
| 2021 Q1 | 60,314,515 | $141,778,049 | +$12,436,479 | $2.35 | 90 |
| 2020 Q4 | 55,072,841 | $96,924,151 | +$3,142,777 | $1.76 | 78 |
| 2020 Q3 | 53,561,495 | $50,165,088 | -$1,850,541 | $0.94 | 65 |
| 2020 Q2 | 55,701,303 | $48,461,276 | -$6,974,131 | $0.87 | 80 |
| 2020 Q1 | 63,835,650 | $52,851,654 | +$405,531 | $0.83 | 81 |